Monday September 9, 2013 0 commentsBOULDER - ArcherDX, a Boulder developer of NGS-based kits and software solutions for use in investigating cancer, has been acquired by Massachusetts-based Enzymatics Inc., a producer of reagents, kits and assays.
Enzymatics said the deal consists of cash, equity and potential milestones worth up to $50 million. Jason Myers, co-founder and CEO of ArcherDx, will join Enzymatics as chief scientific officer.
"An unprecedented growth in genomics for health care is fueling greater demand for faster, more accurate and more cost-effective sequencing applications," said Jon DiVincenzo, Enzymatics' president and CEO.
"We are seeing double-digit growth in the placement of new sequencers every year and broad adoption of genomic technologies across clinical communities. Enzymatics, which already supplies reagents and kits to approximately 80 percent of the NGS industry - together with ArcherDx - will bring novel sequencing applications more directly to clinical researchers."
For more information, visit www.enzymatics.com.